肾功能衰竭患者建立不同血管通路血液净化治疗的疗效评价

Evaluation of therapeutic effect of blood purification through different vascular pathways in patients with renal failure

目的探讨不同血管通路的建立对临床收治肾功能衰竭患者血液净化疗效的影响。方法选取84例本院收治的肾功能衰竭病例,时间范围介于2017年5月-2018年5月,就AVF (观察组,n=42)与CTC (对照组,n=42) Hb、TP、BUN、Scr、Kt/V、URR以及并发症率展开对比。结果 2组透析前后Hb、TP检测数据无明显差异(P>0.05),BUN、Scr、CRP检测数据与透析前相比较有显著下降(P<0.05),但组间数据仅CRP有显著差异(P<0.05);2组肾功能衰竭病患计算所得Kt/V、URR值相较无统计学意义(P>0.05);观察组病例并发症率为4.76%,相较对照组19.05%低,差异具统计学意义(P<0.05)。结论在临床予以肾功能衰竭病患维持性血液净化过程中,AVF或CTC均为稳定、有效的血管通路,对透析效果无较大差异化影响,但AVF血管通路相对更易实现,且并发症率更低,故可为首选。

Objective To investigate the effect of different vascular pathways on blood purification in patients with renal failure. Methods 84 cases of renal failure were selected from May 2017 to May 2018. The AVF(observation group, n=42) and CTC(control group, n=42) Hb, TP, BUN, Scr, Kt/V, URR and complication rate were compared.Results There was no significant difference in Hb and TP test data between the two groups before and after dialysis(P > 0.05). BUN, Scr and CRP test data were significantly decreased compared with those before dialysis(P < 0.05),but only CRP was significantly different between the two groups(P < 0.05). There was no significant difference in Kt/V and URR values between the two groups(P > 0.05). The complication rate of the observation group was 4.76%,which was lower than that of the control group(P < 0.05). Conclusion AVF or CTC are stable and effective vascular pathways in maintaining blood purification in patients with renal failure,and have no significant difference in the effect of dialysis,but AVF vascular pathway is relatively easier to achieve and has lower complication rate,so it is the first choice.